954 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Plotkin Financial Advisors LLC

Plotkin Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 954 shares of the company's stock, valued at approximately $845,000.

Other large investors have also recently made changes to their positions in the company. Timber Creek Capital Management LLC grew its stake in Eli Lilly and Company by 0.7% during the 3rd quarter. Timber Creek Capital Management LLC now owns 12,632 shares of the company's stock worth $11,191,000 after buying an additional 86 shares during the last quarter. Tradition Wealth Management LLC grew its stake in Eli Lilly and Company by 14.0% during the 3rd quarter. Tradition Wealth Management LLC now owns 1,403 shares of the company's stock worth $1,243,000 after buying an additional 172 shares during the last quarter. Encompass More Asset Management purchased a new position in Eli Lilly and Company during the 3rd quarter worth $386,000. Acropolis Investment Management LLC grew its stake in Eli Lilly and Company by 2.9% during the 3rd quarter. Acropolis Investment Management LLC now owns 1,666 shares of the company's stock worth $1,476,000 after buying an additional 47 shares during the last quarter. Finally, L.M. Kohn & Company grew its stake in Eli Lilly and Company by 13.4% during the 3rd quarter. L.M. Kohn & Company now owns 2,725 shares of the company's stock worth $2,414,000 after buying an additional 323 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $7.16 during trading on Friday, hitting $795.35. 2,206,918 shares of the stock were exchanged, compared to its average volume of 4,869,603. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a market cap of $755.04 billion, a PE ratio of 85.98, a P/E/G ratio of 3.01 and a beta of 0.43. The company has a fifty day moving average price of $851.90 and a two-hundred day moving average price of $870.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company's revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.65%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company's stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research note on Thursday, October 31st. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an "overweight" rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Redburn Atlantic upgraded Eli Lilly and Company to a "hold" rating in a research note on Monday, November 4th. Finally, Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,007.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.